ACM-1
Phase 1Small molecule
ACM-1 is one of 44 small molecule programs targeting Vascular Disease. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
66 competitors in Vascular Disease
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Repatha
AmgenApproved
Precose
BayerApproved
Colcrys
Alnylam PharmaceuticalsApproved
Letairis
GileadApproved
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Andriol
AAuxilium
Approved
Donepezil Hydrochloride
EisaiApproved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Cleviprex
Chiesi Farmaceutici S.p.A.Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ACM-1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SSun Yat-sen University